Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Test Detects Difficult-to-Diagnose Chronic Blood Cancer

By LabMedica International staff writers
Posted on 26 Dec 2013
The current blood test used to diagnose blood cancer works by identifying mutation in a specific gene; however, it is not necessary that the gene should be present in every patient.

The Janus kinase 2 gene (JAK2) occurs in many myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative neoplasms with nonmutated JAK2 is obscure, and the diagnosis of these neoplasms remains a challenge.

A collaborating team of scientists from the University of Cambridge (UK) and the Wellcome Trust Sanger Institute (Hinxton, UK) and other institutes performed exome sequencing of samples obtained from 151 patients with myeloproliferative neoplasms. More...
The mutation status of the gene encoding calreticulin (CALR) was assessed in an additional 1,345 hematologic cancers, 1,517 other cancers, and 550 controls. They established phylogenetic trees using hematopoietic colonies and assessed calreticulin subcellular localization using immunofluorescence and flow cytometry.

The team analyzed the results of exome sequencing of DNA from granulocytes and constitutional DNA obtained from purified T cells or buccal cells in 168 patients with myeloproliferative neoplasms. The identification of appropriate constitutional DNA samples is a challenge among patients with myeloproliferative neoplasms, since circulating T cells and buccal cells may be contaminated by neoplastic cells. On sequencing the patients' DNA, the scientists identified a new gene called CALR, the mutations of which were associated with chronic blood cancer. They also noticed a rise in platelet counts and a decline in hemoglobin levels associated with JAK2 mutation.

The authors concluded that detection of CALR mutations in peripheral blood could potentially be used as a diagnostic tool in the same way that tests for JAK2 mutations have simplified and improved the accuracy of diagnosis of patients with myeloproliferative neoplasms worldwide. Peter J. Campbell, MB, ChB, PhD, from the Sanger Institute, who co-led the research, said, “There is now a sense of completeness with these disorders , the vast majority of our patients can now have a definitive genetic diagnosis made. In the next year or two, we will see these genetic technologies increasingly used in the diagnosis of all cancers, especially blood cancers.” The study was published on December 10, 2013, in the New England Journal of Medicine.

Related Links:

University of Cambridge
Wellcome Trust Sanger Institute 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.